Indication: VONVENDI [von Willebrand factor (recombinant)] is used in adults (age 18 years and older) diagnosed with von Willebrand disease to: treat and control bleeding episodes and prevent excessive bleeding during and after surgery


2016: The year recombinant VWF treatment became available

Learn about a treatment option

Purified to remove FVIII

People with VWD have naturally varying levels of factor VIII (FVIII), an essential blood clotting protein. Therefore, not every person with VWD or every bleed requires FVIII replacement.6

VONVENDI® [von Willebrand factor (Recombinant)], indicated for use in adults with von Willebrand disease. It is a manufactured recombinant product and is the first product to offer a purified recombinant von Willebrand factor (rVWF).4

VONVENDI allows healthcare providers to dose rVWF with or without rFVIII based on each patient’s individual requirements.4

Selected Important Risk Information

You should not use VONVENDI [von Willebrand factor (Recombinant)] if you:

  • Are allergic to any ingredients in VONVENDI.
  • Are allergic to mice or hamsters.

Tell your healthcare provider if you are pregnant or breastfeeding because VONVENDI may not be right for you.

Your first dose of VONVENDI for each bleeding episode may be administered with a recombinant factor VIII as instructed by your healthcare provider.

Representative Finder: Find your local Shire representative

Representative finder

A Shire representative can answer your questions about VONVENDI®

Help me out
Stay updated: Sign up for information from Shire

Stay updated

Sign up for information from Shire

Sign me up!